

# Leishmaniasis

# TUNISIA

**2014**
*Published in July 2016*

## Country General Information (WHO, 2013)

Total population:	10,997,000	Age group <15/>14 years, %:	23% / 77%
Gender (% F/M):	50.4% / 49.6%	Life expectancy at birth in years (F/M):	78 / 74
GDP (PPP int \$):	10 960	Number of 1st sub-national administrative level divisions, name:	24, Governorate
Income status:	Upper middle		



## Epidemiology

	VL	CL	PKDL	MCL
Endemicity status:	Endemic	Endemic	Non endemic	Non endemic
Number of new cases (incidence):	44	3368	N/A	N/A
Number of relapse cases:	No data	No data	N/A	N/A
Total number of cases:	44	3368	N/A	N/A
Imported cases (n, %):	0 0%	0 0%	No data	No data
Gender distribution (% F):	48%	52%	N/A	N/A
Age group distribution (% , <5/5-14/>14):	(70 / 20 / 9)	(16 / 18 / 66)	N/A	N/A
Incidence rate (cases/10 000 population in endemic areas):	0.04	5.67	N/A	N/A
Number of endemic 1st sub-national administrative level divisions (n):	No data	No data	N/A	N/A
Population at risk <sup>1</sup> (% , n/total):	90% (9901000 / 10996600)	54% (5935000 / 10996600)	N/A	N/A
Was there any outbreak?	No	No	N/A	N/A
Number of new <sup>2</sup> foci:	0	0	N/A	N/A



N/A = not applicable VL = visceral leishmaniasis CL = cutaneous leishmaniasis PKDL = post-kala-azar dermal leishmaniasis MCL = mucocutaneous leishmaniasis

## Monthly distribution of new cases January-December

2014	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
VL	0	0	5	5	4	4	15	1	0	3	1	6
CL	704	267	177	88	65	30	40	39	104	267	648	939



## Incidence rate/10 000 population and number of new CL (left) and new (primary) VL (right) cases from 1998 to 2014




<sup>1</sup> Defined as "Number of people living in 1st sub-national administrative level endemic areas"

<sup>2</sup> For this reporting period, an area at the 1st sub-national administrative level reporting cases for the first time ever


<sup>3</sup> Incidence rate at the national level

## Distribution of new CL (left) and new VL (right) cases

Incidence of CL in Tunisia in 2014 at governorate level per 10 000 population



Incidence of VL in Tunisia in 2014 at governorate level per 10 000 population



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Map production: WHO/HTM/NTD/IDM

## Control and surveillance

Year Leishmaniasis National Control Programme (LNCP) was established:	1984	Year latest national guidelines were published:	2012
Type of surveillance:	Integrated	Is leishmaniasis a notifiable disease (mandatory reporting)?	Yes
Is there a vector control programme?	No	Is there a reservoir host control programme?	Yes
Type of insecticide used for IRS:	Not available	Number of leishmaniasis health facilities:	1289

## Diagnosis

	VL	CL	PKDL	MCL
Number of people screened actively for:	No data	No data	N/A	N/A
Number of people screened passively for:	No data	3368	N/A	N/A
VL cases diagnosed by RDT* (%, RDT+/total VL cases):	No data	N/A	N/A	N/A
Proportion of positive RDT* (%, RDT+/total RDT):	No data	N/A	N/A	N/A
Cases diagnosed by direct exam (parasitology) (% , # slides +/total cases):	100% (44 / 44)	No data	N/A	N/A
Proportion of positive slides (%, slides +/total slides):	100% (44 / 44)	No data	N/A	N/A
Cases diagnosed clinically (%, nb clinical cases/total cases):	100% (44 / 44)	100% (3368 / 3368)	N/A	N/A
Percentage of cases with HIV-VL coinfection:	No data	N/A	N/A	N/A

\* These indicators only apply for new (primary) VL cases VL = visceral leishmaniasis CL = cutaneous leishmaniasis PKDL = post-kala-azar dermal leishmaniasis  
N/A = not applicable RDT = rapid diagnostic test HIV = human immunodeficiency virus MCL = mucocutaneous leishmaniasis

## Treatment and medicines

Is treatment provided free of charge in the public sector?	Yes
Antileishmanial medicines included in the national List of Essential Medicines:	Meglumine antimoniate

TREATMENT OUTCOME	VL
Proportion of relapse cases: <sup>4</sup>	No data
Initial cure rate:	No data
Failure <sup>5</sup> rate:	No data
Case-fatality rate:	No data

<sup>4</sup> A relapse case in this country is defined as: No definition available

<sup>5</sup> A failure case in this country is defined as: No definition available